TRIGLUMA GLP1- GIP & GLUCAGON PEPTIDE Advanced Peptide Therapy for Weight Management and Metabolic Health

OVERVIEW

TRIGLUMA is a next-generation peptide introduced by JN Beauty Solutions®, belonging to the GLP-1/GIP/Glucagon peptide (triple-receptor agonist) class. It is being developed to support the management of obesity, type 2 diabetes, and other metabolic disorders.

Unlike conventional weight-loss medications, TRIGLUMA simultaneously targets multiple hormonal pathways to address the root causes of metabolic imbalance. By activating three receptors at once, it offers a comprehensive “metabolic reset,” enhancing fat burning, improving insulin sensitivity, and promoting sustainable weight loss.

HOW TRIGLUMA WORKS

After subcutaneous injection, TRIGLUMA activates three key receptors:

 

  • GLP-1: Slows gastric emptying, reduces appetite, stimulates insulin secretion, and suppresses glucagon release.
  • GIP: Enhances insulin secretion in response to elevated glucose levels, improves insulin sensitivity, and helps regulate fat storage.
  • Glucagon: Promotes lipolysis (fat breakdown), increases energy expenditure through thermogenesis, and supports fat burning even at rest.

 

This triple mechanism results in reduced calorie intake, better glycemic control, and improved energy utilization, positioning TRIGLUMA as one of the most advanced peptides in modern metabolic care.

 

CLINICAL RESEARCH HIGHLIGHTS

(Data from Eli Lilly’s Phase 2 and Phase 3 trials – updated as of April 2026)

TRIGLUMA (active ingredient: Retatrutide) has been evaluated in multiple large-scale clinical trials:

 

  • Phase 2 Trial (48 weeks): Participants with obesity receiving 12 mg weekly achieved an average weight loss of 24.2%, with continued weight reduction observed at the end of the study and no plateau reached.
  • Phase 3 TRIUMPH-4 Trial (topline results, December 2025): In adults with obesity or overweight and knee osteoarthritis (without diabetes), the 12 mg dose delivered an average weight loss of 28.7% (approximately 71.2 lbs / 32.3 kg) over 68 weeks. Significant improvements in knee pain and physical function were also reported.
  • Phase 3 TRANSCEND-T2D-1 Trial (topline results, March 2026): In patients with type 2 diabetes, the 12 mg dose achieved an average HbA1c reduction of up to 2.0% and mean weight loss of 16.8% (approximately 36.6 lbs / 16.6 kg) at 40 weeks. Weight loss continued without plateau through the end of the treatment period.

 

ADDITIONAL OBSERVED BENEFITS INCLUDE:

 

  • Substantial reduction in visceral fat, improved lipid profiles, and lowered blood pressure.
  • Enhanced fat oxidation and better preservation of lean muscle mass when combined with adequate protein intake and resistance training.
  • Promising potential in reducing liver fat and improving liver function markers in patients with NAFLD/NASH.

 

Note: These results come from ongoing clinical trials. Individual outcomes may vary, and long-term safety and efficacy data are still being collected.

 

ADMINISTRATION

Dosage Form: Subcutaneous injection (once weekly)

Dosing in Trials: Starts at 1 mg per week, with gradual titration up to 12 mg per week based on tolerability and treatment goals.

 

COMMON SIDE EFFECTS

Gastrointestinal issues such as nausea, vomiting, and diarrhea (most common during dose escalation).

Dizziness or fatigue (often related to blood pressure changes).

Potential for muscle loss if protein intake and resistance training are not adequately maintained.

 

WHO SHOULD NOT USE TRIGLUMA?

 

TRIGLUMA is contraindicated in the following groups:

  • Individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
  • Patients with a history of pancreatitis.
  • Those with severe liver or kidney impairment.
  • Pregnant or breastfeeding women.
  • Individuals with known hypersensitivity to GLP-1, GIP, or glucagon analogs.
  • Patients with severe gastrointestinal disorders or a history of severe hypoglycemia.

 

IMPORTANT DISCLAIMER

  • TRIGLUMA is an investigational peptide and has NOT yet been approved by the U.S. FDA or any other regulatory authority for commercial or prescription use.
  • All information provided here is for reference only and is based on publicly available data from Eli Lilly’s Phase 2 and Phase 3 clinical trials. Results may differ between individuals, and the long-term safety profile has not been fully established.
  • This product must only be used under the strict supervision and prescription of a qualified physician. JN Beauty Solutions® does not replace professional medical advice. We strongly advise against self-administration or unauthorized purchase until full regulatory approval is granted.

 

HOW DOES TRIGLUMA COMPARE TO OTHER PEPTIDES?

Compared to Semaglutide (GLP-1 agonist only) and Tirzepatide (GLP-1 + GIP dual agonist), TRIGLUMA offers a superior triple-agonist mechanism by also activating the glucagon receptor. This not only enhances weight-loss efficacy but also increases energy expenditure and metabolic flexibility.

In early and Phase 3 trials, TRIGLUMA has consistently shown greater reductions in body weight and blood glucose markers than previous generations of peptides.

 

CONCLUSION

TRIGLUMA represents a major breakthrough in metabolic peptide therapy. With its powerful ability to suppress appetite, regulate glucose levels, and stimulate fat metabolism, it has the potential to become one of the most effective weight-management peptides available.

TRIGLUMA remains in Phase 3 clinical development and is not yet FDA-approved.

 

For more information about TRIGLUMA, please contact:

JN Beauty Solutions®

Beauty From Science

 

#BeautySolutionsUSA #JnBeautySolutions #TRIGLUMA #GLP1GIPGlucagonPeptide #WeightLossPeptide